explore -WSS

explore

author：explore 2025-09-27 12:55:00 - browse：1

The sign of University of Texas MD Anderson Cancer Center in Houston, Texas in front of the Sheikh Zayed Building — coverage from STAT — Adobe

Early last year, MD Anderson Cancer Center leadership had a problem on their hands: a contentious dispute between one of its most powerful researchers and a junior scientist over authorship, credit, and charges of verbal abuse. High-ranking officials at the cancer center tried — and failed — to resolve the feud, and documents obtained by STAT shed new light on the deep divisions at the heart of this case.

The Texas cancer center outsourced assessing the conflict between early-career nephrologist Jamie Lin and leading oncologist Padmanee Sharma to the law firm Ropes & Gray. The firm investigated the authorship and scientific credit portions of the dispute and concluded that Sharma was likely responsible for a scientific hypothesis at the heart of the feud and should be named as a co-senior author on a key manuscript.

But a separate investigation, commissioned by Lin and conducted by a former official at the federal Office of Research Integrity, tells a somewhat different story. That review looked into plagiarism after Sharma claimed Lin had wrongly omitted the senior researcher as an author from a manuscript built on research to which Sharma contributed. But this second investigation found no evidence of plagiarism between two manuscripts submitted to the journals Cancer Immunology Research and Journal of Clinical Investigation Insight.

Lin provided STAT with copies of an executive summary of the Ropes & Gray investigation as well as the conclusions of the plagiarism investigation. These documents are alluded to in legal filings but have not been previously reported. Lin has filed a lawsuit against Sharma in the Harris County District Court alleging retaliation, harassment, threatening, and intellectual theft by Sharma; she’s also asking for $5 million in damages.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Pioneering cancer drug will cost $475,000. Analysts call it a bargain

WSS

Millions may soon lose Medicaid when they don't have to

Patients, doctors are clashing about side effects of hormonal birth control

Food as medicine: Medically tailored meals may get standardized

Eli Lilly’s Mounjaro succeeds in second weight

The Readout: Lenmeldy, GLP

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

explore

explore

leisure time

How one medical school became remarkably diverse

Mom launches Girl Scout troop for LGBTQ youth in Texas

Hollywood unions extend contract negotiations for actors

There's no autism epidemic. It's an autism diagnosis epidemic

Peter Hotez and the public health issue of online harassment

Altering the blood type of lungs raises potential for universal organs for transplants

Heart attack and stroke risk calculators need revising

Millions may soon lose Medicaid when they don't have to

Hepatitis C has a cure — but many Americans still lack access to it

There's no autism epidemic. It's an autism diagnosis epidemic

focus

Readout Newsletter: Merck, Vertex, and Viking updates

Washington mulls new rules to avert another Change Healthcare

Why the world’s most expensive drug might be worth the price

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Steward Health Care has deal to sell doctor network to UnitedHealth

Supreme Court mifepristone arguments center on docs' right to sue

focus

focus

explore

leisure time